Preclinical Imaging Market Research Report: by Product (Optical Imaging, Nuclear Imaging, Micro-MRI, Micro-Ultrasound, Micro-CT, Photoacoustic Imaging System), by Reagent (Optical, Nuclear, CT Contrast Agents, MRI Contrast Agents) - Forecast Till 2030

Preclinical Imaging Market Overview

The preclinical imaging market is expected to reach USD 5.4 billion by 2030 at 3.2% CAGR during the forecast period 2022-2030. The process refers to the vision of living animals for analysis reasons. For example, drug development and imaging modes are crucial for researchers. Other factors that impact market growth are increased funding to support preclinical research and growing market demand is also projected to influence the market's growth and push it forward. However, the high installation and operational costs and strict government regulations in preclinical research will impede the market's growth over the coming years. During the last few years, the market has gained a lot of growth and attributed the growth. The presence of well-established players and innovative technologies in the field of molecular imaging and also the rise in the funding will support the market in the forecast period.

Segmentation

The preclinical imaging market has been segmented into modality, reagent, and region.

Based on modality, market is segmented into optical imaging systems, nuclear imaging systems, micro-MRI, micro-ultrasound, micro-CT, photoacoustic imaging system, and magnetic particle imaging systems. The optical imaging systems segment is expected to account for the largest share segment of the market in 2017.

Based on reagent, preclinical imaging market is segmented into preclinical optical imaging reagents, preclinical nuclear imaging reagents, preclinical MRI contrast agents, preclinical ultrasound contrast agents, and preclinical CT contrast agents. The preclinical optical imaging reagents segment is expected to account for the largest share segment of the market in 2017.

The preclinical imaging market segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas further segmented into North America and South America, with the North American market divided into the US and Canada.

The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The preclinical imaging market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The preclinical imaging market in the Middle East & Africa segmented into the Middle East and Africa.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the preclinical imaging market owing to a well-established player, technological advancements in the field of molecular imaging, increasing market demand for non-invasive small-animal imaging techniques, and increasing funding to support preclinical researches.

Europe is expected to hold the second largest position in the market. The market growth in this region is attributed to increasing funding to support preclinical researches.

The preclinical imaging market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region.

The Middle East & Africa has the least share of the preclinical imaging market.

Recent Developments

March 2022 – Veristat, to strengthen its relations in the European market, has announced the acquisition of Switzerland-based SFL (Solutions for Life Sciences) for an unrevealed price. A Southborough, Massachusetts-based CRO, Veristat, stated that the deal would offer access to an SFL team with deep experience encompassing a variety of therapies in orphan disease and oncology seeking further treatments, which could blend artificial intelligence, diagnostics, and devices. The company believes that the SFL's background in the EU, the U.K., and the Swiss healthcare systems signify profit for a U.S. company looking to get into those markets.

February 2022 – a global provider of ultra-high-frequency (UHF) ultrasound imaging systems, FUJIFILM VisualSonics, and the European leader in tomographic ultrasound imaging, PIUR IMAGING, has announced the partnership to bring UHF, three-dimensional (3D) ultrasound imaging technology to researchers and clinicians. The technological development helps clinical research assess anomalies in various applications, including MSK, vascular, dermatology, and neurology.

Market of Preclinical Imaging, by Modality

• Optical Imaging Systems




• Bioluminescence/Fluorescence Imaging Systems


• Standalone Fluorescence Imaging Systems


• Optical + X ray/ Optical + CT systems




• Nuclear Imaging Systems




• Micro-PET Systems


• Micro-Spect Systems


• Trimodality (Spect/PET/CT) Systems




• Micro-MRI


• Micro-Ultrasound


• Micro-CT


• Photoacoustic Imaging System


• Magnetic Particle Imaging Systems

Market of Preclinical Imaging, by Reagent

• Preclinical Optical Imaging Reagents




• Bioluminescent Imaging Reagents


• Fluorescent Imaging Reagents




• Preclinical Nuclear Imaging Reagents




• Preclinical PET Tracers


• Preclinical Spect Probes




• Preclinical MRI Contrast Agents


• Preclinical Ultrasound Contrast Agents


• Preclinical CT Contrast Agents

Market of Preclinical Imaging, by Region

• Americas




• North America




• US


• Canada




• South America




• Europe




• Western Europe




• Germany


• France


• Italy


• Spain


• UK




• Rest of Western Europe


• Eastern Europe




• Asia-Pacific




• Japan


• China


• India


• Australia


• South Korea


• Rest of Asia-Pacific




• The Middle East & Africa




• Middle East


• Africa

Market of Preclinical Imaging, by Key Players

• Bruker Corporation (US)


• MR Solutions (UK)


• PerkinElmer (US)


• Fujifilm Holdings Corporation (Japan)


• Milabs B.V. (The Netherlands)


• Mediso Ltd. (Hungary)


• Miltenyi Biotec GmbH (Germany)


• LI-COR, Inc. (US)


• Aspect Imaging (Israel)


• Trifoil Imaging (US)

Recent Development

April 2022

A global leader PerkinElmer is committed to innovating for a healthier world; it recently announced the expansion of its in vivo imaging portfolio with the launch of the Vega® imaging system. This first-of-its-kind ultrasound platform combines hands-free, automated technology with the high-throughput capability to accelerate non-invasive research and drug development studies of cancer, liver and kidney disease, cardiology, and more.

 Researchers from York and Cambridge, U.K., have developed a new sodium magnetic resonance imaging (MRI) technique by doing the recent research on mice. It can detect levels of 23Na in breast tumours, which could help diagnose and monitor breast cancer. It is also useful to indicate the degree of aggressiveness of a tumour and its susceptibility to chemotherapy.

May 2022

In Boston, a new study led by investigators at Massachusetts General Hospital (MGH) shows the impact of early amyloid-β and tau protein accumulation on disrupting connections between brain structures that are important for memory.Intended Audience

• Preclinical Imaging Manufacturers and vendors


• Research organization and CRO


• Various research and consulting firms